国产三抗新药首次公布临床结果

新浪医药11-17

2025 年美国血液学会（ASH）年会将于当地时间 12 月 6 日到 12 月 9 日在美国佛罗里达州奥兰多市召开，目前常规摘要已经公布。齐鲁制药将在本次会议上首次公布下一代GPRC5D×BCMA×CD3三抗 QLS4131在复发或难治性多发性骨髓瘤（RRMM）患者中首次人体试验的初步研究结果。截图来源：ASH 官网QLS4131 是一款 BCMA/GPRC5D/CD3 三抗。临床前数据显示，与...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2584323984?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-17 19:28","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2584323984","market":"us","top_or_hot":-1,"title":"国产三抗新药首次公布临床结果","media":"新浪医药","content":"<div>\n<p>2025 年美国血液学会（ASH）年会将于当地时间 12 月 6 日到 12 月 9 日在美国佛罗里达州奥兰多市召开，目前常规摘要已经公布。齐鲁制药将在本次会议上首次公布下一代GPRC5D×BCMA×CD3三抗 QLS4131在复发或难治性多发性骨髓瘤（RRMM）患者中首次人体试验的初步研究结果。截图来源：ASH 官网QLS4131 是一款 BCMA/GPRC5D/CD3 三抗。临床前数据显示，与...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117223327a4a7ede6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国产三抗新药首次公布临床结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国产三抗新药首次公布临床结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-17 19:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117223327a4a7ede6&s=b><strong>新浪医药</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025 年美国血液学会（ASH）年会将于当地时间 12 月 6 日到 12 月 9 日在美国佛罗里达州奥兰多市召开，目前常规摘要已经公布。齐鲁制药将在本次会议上首次公布下一代GPRC5D×BCMA×CD3三抗 QLS4131在复发或难治性多发性骨髓瘤（RRMM）患者中首次人体试验的初步研究结果。截图来源：ASH 官网QLS4131 是一款 BCMA/GPRC5D/CD3 三抗。临床前数据显示，与...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117223327a4a7ede6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z4B17.USD","symbol_name":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117223327a4a7ede6&s=b","article_id":"2584323984","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117223327a4a7ede6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584323984","pubTimestamp":1763378888,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025 年美国血液学会年会将于当地时间 12 月 6 日到 12 月 9 日在美国佛罗里达州奥兰多市召开，目前常规摘要已经公布。齐鲁制药将在本次会议上首次公布下一代GPRC5D×BCMA×CD3三抗 QLS4131在复发或难治性多发性骨髓瘤患者中首次人体试验的初步研究结果。这是一项评价QLS4131 在 RRMM 患者中的安全性、耐受性、药代动力学、免疫原性以及初步有效性的 I 期临床研究。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","PR":"Permian Resources Corp","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","JNJ":"强生","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","BK4007":"制药","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","TRAE":"Triton American Energy Corp.","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","BK4187":"航天航空与国防","BK4121":"生命科学工具和服务","BK4019":"再保险","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","CRS":"卡朋特科技","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","KG":"Kestrel","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4534":"瑞士信贷持仓","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","LU0070217475.USD":"JPM GLOBAL SELECT EQUITY \"A\" ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","MTD":"梅特勒-托利多","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","ASH":"Ashland"},"translate_title":"Domestic triple antibody new drug announces clinical results for the first time","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTD":1,"JNJ":0.9,"CRS":1,"PR":1,"TRAE":1,"KG":0.9,"ASH":1},"content_text":"2025 年美国血液学会（ASH）年会将于当地时间 12 月 6 日到 12 月 9 日在美国佛罗里达州奥兰多市召开，目前常规摘要已经公布。齐鲁制药将在本次会议上首次公布下一代GPRC5D×BCMA×CD3三抗 QLS4131在复发或难治性多发性骨髓瘤（RRMM）患者中首次人体试验的初步研究结果。截图来源：ASH 官网QLS4131 是一款 BCMA/GPRC5D/CD3 三抗。临床前数据显示，与对标品相比，QLS4131 对多发性骨髓瘤细胞系表现出更高的亲和力，能够有效清除双靶点（BCMA 和 GPRC5D）和单靶点（BCMA 或 GPRC5D）表达的肿瘤细胞，其肿瘤细胞杀伤活性显著高于对标品。这是一项评价QLS4131 在 RRMM 患者中的安全性、耐受性、药代动力学、免疫原性以及初步有效性的 I 期临床研究（NCT06500507）。在“剂量递增阶段”，齐鲁制药招募了那些患有可测量的 RRMM 且在现有治疗后病情出现进展或无法耐受现有治疗的患者。剂量递增包括：静脉注射（IV）剂量从 0.06µg/kg递增至 30µg/kg，每周一次（QW）给药；皮下注射（SC）剂量从 30µg/kg递增至 600µg/kg，每两周一次（Q2W）给药。患者在首次目标剂量（从 3µg/kg剂量水平开始）之前会接受 1 或 2 次递增剂量（SUD），以减轻细胞因子释放综合征（CRS）。截至 2025 年 7 月 15 日，共有 17 名患者接受了 QLS4131 治疗，剂量范围为 0.06 至 30µg/kg（IV，QW）。此外，另有 3 名入组患者接受了 30µg/kg的 QLS4131 治疗（SC，Q2W）。患者的中位年龄为 59 岁，中位既往治疗线数为 3。其中 64.7% 的患者曾接受过 3 线及以上的治疗，35% 的患者曾接受过干细胞移植。结果显示，在 ≥1µg/kg剂量组中观察到了反应。在15 名接受QLS4131 静脉注射治疗且符合反应评估标准的患者中，ORR 为 60%（≥VGPR 40%）。在 30µg/kg剂量组中，100% 的患者达到 VGPR 及以上的缓解。此外，在 10µg/kg 静脉注射剂量组中，有2 名患者先前接受过 BCMA 靶向的 CAR-T/CAR-NK 治疗而失败，目前其中1 例达到严格意义上的完全缓解(SCR)，另 1 例达到部分缓解(PR)。安全性方面，QLS4131 具有总体可控的耐受性。未出现剂量限制毒性反应（DLT），也未达到最大耐受剂量（MTD）。最常见的治疗相关不良事件（TRAE）为血细胞减少和 CRS，CRS 的总体发生率为 80%。未出现免疫效应细胞相关神经毒性综合征（ICANS）。研究者得出结论，QLS4131毒性可耐受，未观察到 DLT，且与竞争对手(如强生 JNJ-79635322)公布的数据相比，GPRC5D 相关不良反应的发生率较低。主要疗效数据表明，即使在低剂量水平下也观察到了积极的反应。该试验仍在进行中，MTD、RP2D 以及 DLT 还需确定。全球在研的GPRC5D×BCMA×CD3 三抗共有 13 款，6 款已经进入临床阶段，分别来自天广实（MBS314）、信达（IBI3003）、齐鲁（QLS4131）、先声药业/艾伯维（SIM0500）、强生（JNJ-79635322）。来源：Insight 数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584323984","isCrawlerRequest":true}